



Writing errors in ALS related to loss of neuronal integrity in the anterior cingulate gyrus

Ichiro Yabe ^{a,*}, Sachiko Tsuji-Akimoto ^a, Tohru Shiga ^b, Shinsuke Hamada ^a, Kenji Hirata ^b, Mika Otsuki ^c, Yuji Kuge ^d, Nagara Tamaki ^b, Hidenao Sasaki ^{a,**}

^a Department of Neurology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

^b Department of Nuclear Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan

^c School of Psychological Science, Health Sciences University of Hokkaido, Sapporo, Japan

^d Department of Trace Kinetics & Bioanalysis, Hokkaido University Graduate School of Medicine, Sapporo, Japan

ARTICLE INFO

Article history:

Received 27 January 2011

Received in revised form 29 November 2011

Accepted 30 November 2011

Available online 4 January 2012

Keywords:

Amyotrophic lateral sclerosis

Writing error

Cognitive dysfunction

PET

Anterior cingulate gyrus

ABSTRACT

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by loss of motor neuron and various cognitive deficits including writing errors. ¹¹C-flumazenil (FMZ), the positron emission tomography (PET) GABA_A receptor ligand, is a marker of cortical dysfunction. The objective of this study was to investigate the relationship between cognitive deficits and loss of neuronal integrity in ALS patients using ¹¹C-FMZ PET. Ten patients with ALS underwent both neuropsychological tests and ¹¹C-FMZ-PET. The binding potential (BP) of FMZ was calculated from ¹¹C-FMZ PET images. There were no significant correlations between the BP and most test scores except for the writing error index (WEI), which was measured by the modified Western Aphasia Battery – VB (WAB-IVB) test. The severity of writing error was associated with loss of neuronal integrity in the bilateral anterior cingulate gyrus with mild right predominance ($n=9$; $x=4$ mm, $y=36$ mm, $z=4$ mm, $Z=5.1$). The results showed that writing errors in our patients with ALS were related to dysfunction in the anterior cingulate gyrus.

© 2011 Elsevier B.V. All rights reserved.

1. Introduction

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder characterized by progressive muscular atrophy and weakness with upper motor neuron impairment. It has traditionally been believed that intelligence is spared except in a small proportion of patients. Mitsuyama [1] described patients with dementia as having memory difficulty, global intellectual impairment, personality change, emotional disorder and loss of spontaneous speech. These deficits are consistent with fronto-temporal lobar degeneration (FTLD).

Recent studies have shed light on the mild cognitive impairment of ALS patients who do not meet the criteria of FTLD [2]. The published rate of ALS patients with cognitive impairment varies from 3% to 52% [3–6]. As a result of intensive explorations of frontal lobe function, impairment of verbal fluency and executive function have been identified as specific deficits in ALS [4,7–11]. Some Japanese investigators described that ALS

patients frequently had agraphia without aphasia regardless of whether they had dementia [12–15]. Omission of a Japanese *kana* letter was the most frequent error, and substitution, displacement, and incorrect letters were also often observed. The pattern of errors looked like they occurred from a frontal lobe lesion, which was supported by the finding of a reduction in cerebral blood flow in the frontal lobe in a single photon emission computed tomography (SPECT) study of a few cases. An autopsied case with progressive agraphia and ALS-D showed marked degeneration of the left middle frontal gyrus including Exner's area [16]. Thus, dysfunction of the frontal lobe was suspected as being responsible for the writing error in patients with ALS; however, because the number of reported cases was small, the pathological locus has not been conclusively identified.

The GABA_A receptor ligand ¹¹C-flumazenil (FMZ) is a probe used in positron emission tomography (PET) for the central-type benzodiazepine receptor (BZR) [17]. In vitro studies of specimens obtained from patients with epileptogenic brain lesions demonstrated altered GABAergic neurotransmission in the perilesional epileptic cortex [18,19]. Therefore, FMZ PET is a sensitive, noninvasive method for visualizing focal cortical dysfunction that may represent epileptogenic zones. Because GABA receptors are abundant in the cortex, cerebral BZRs co-located with GABA_A receptors can also be used as a marker of neuronal viability [20].

* Corresponding author. Tel.: +81 11 706 6028; fax: +81 11 700 5356.

** Corresponding author.

E-mail addresses: yabe@med.hokudai.ac.jp (I. Yabe), h-isasak@med.hokudai.ac.jp (H. Sasaki).

In this study, we performed several cognitive screening tests in non-demented ALS patients and identified the locus of their cognitive symptoms using FMZ PET.

2. Subjects and methods

2.1. Subjects

Ten patients with sporadic ALS agreed to participate in this study from September 2007 to June 2008. At the time of the examination, the patients were in the following categories of the revised El Escorial Criteria: 2 patients definite, 4 probable, 3 possible, and 1 suspected. All patients deteriorated in the following year, developing probable or definite ALS by 2010 [21]. The lesion at onset was located in the brainstem in 7 cases, cervical region in 2 cases and lumbosacral region in 1 case. Table 1 shows characteristics of the patients. No patient had respiratory symptom, and no patient had highly impaired forced vital capacity (%FVC > 70). One patient had encephalitis several years prior without any sequelae while the score on the Raven Progressive Colored Matrices (RPCM) was lower than –2SD. Another patient was left-handed. Image analysis was performed within one month after having administered the neuropsychological examinations.

All patients gave written informed consent according to the Helsinki Declaration. This study was approved by the Ethics Committee of Hokkaido University Graduate School of Medicine.

2.2. Neuropsychological examination

Since we speculated that patients with ALS tended to have writing errors as a result of frontal lobe disorder, we mainly examined their ability of writing and frontal lobe function. A comprehensive test battery was developed as shown in Table 2. All ten patients underwent the neuropsychological tests. To confirm general cognition, all subjects were administered the Japanese Raven's colored progressive matrices test (RPCM). One of the ten patients could not perform the writing and trail-making tests at all because of disability of the dominant hand. Another patient could not perform the trail-making test because of fatigue. In addition, two patients with severe bulbar sign could not perform the verbal repetition test.

To quantify the writing errors, we used the original writing error index (WEI), which we had developed in our previous study [15]. Briefly, the patients were shown a picture of people at a picnic and were requested to give a written description of the photograph. The WEI was calculated as follows:

$$\text{WEI} = (\text{number of errors/total number of written words}) \times 100.$$

Errors include omissions, replacements, spelling rearrangements, nonexistent letters (ideogram, or *kana*) and nonexistent characters (morphograms, or *Kanji*). An incomprehensible or grammatically strange sentence was considered to be one error.

2.3. ^{11}C -flumazenil positron emission tomography

PET was performed using the ECAT EXACT HR+ scanner (Asahi-Siemens, Tokyo, Japan) with in-plane and axial resolutions of

Table 2
Neuropsychological test scores.

Test	n	Mean \pm SD	FS
General intelligence			
Raven's colored progressive matrix test (RPCM)	10	29.8 \pm 44	37
Picture arrangement (WAIS-R IV-3, 4, 5)	10	1.6 \pm 1.1*	3
Attention			
Trail-making tests A (TMT-A)	8	59.7 \pm 35.3 s	
Trail-making tests B (TMT-B)	8	154.9 \pm 71.8 s	
(TMT-B) – (TMT-A)	8	84.4 \pm 46.4 s	
Frontal assessment battery: sensitivity to interference and inhibitory control			
FAB-4: conflicting instruction	10	2.6 \pm 1.0	3
FAB-5: go/no-go test	10	2.1 \pm 1.2	3
Verbal function			
Repetition (WAB-III)	8	98.6 \pm 1.9	100
Composition, writing error index (WEI**)	9	6.0 \pm 0.1***	0

* The result in healthy controls was 2.9 ± 0.4 (n = 18) [15]. $p < 0.05$ vs. healthy controls.

** The WEI was calculated as described previously [15].

*** The result in healthy controls was 2.3 ± 3.0 (n = 14) [15]. $P < 0.05$ vs. healthy controls.

SD: standard deviation, FS: full score, n: number of patients, s: seconds.

4.5 mm and 3.71 mm, respectively. Photon attenuation was corrected with a 5 min transmission scan. FMZ PET procedures were performed as previously described [22].

Dynamic FMZ PET scans were acquired in all patients. Drugs that affect BZR were withdrawn at least one week before the FMZ PET studies. The injected dose of FMZ was 370 MBq in each patient. A set of 27 sequential PET frames of increasing duration were obtained over 60 min after FMZ injection, according to the following protocol: 40 s \times 1 frame, 20 s \times 10 frames, 60 s \times 4 frames, 180 s \times 4 frames and 300 s \times 8 frames. A reference tissue compartment model was used for noninvasive estimation of binding potential (BP) with a time–activity curve in the pons as an indirect input function [22]. The equations that we used were previously described [22]. BP was estimated by the nonlinear least squares method using the equations for the reference tissue compartment model [23].

2.4. MRI

MRI was performed using a 1.5 T scanner (Magnetome Vision or Magnetome Symphony, Asahi-Siemens, Tokyo, Japan). Three-dimensional T1-weighted images were acquired with the magnetization-prepared rapid gradient-echo (MP-RAGE) sequence. Transaxial T2 and T2*-weighted images and FLAIR images were acquired. All images were acquired with 5 mm slice thickness and no slice gap. Coronal and sagittal images were obtained in some cases.

2.5. Image analysis

Image analysis was performed using statistical parametric mapping (SPM2 and SPM5 softwares) in Matlab version 7.6 (Mathworks, Natick, MA, USA) on a Microsoft Windows-based workstation [24]. The ^{11}C -flumazenil binding potential images (FMZ BP) were first co-registered with the three-dimensional MR images by the mutual information technique. The three-dimensional MR images were spatially normalized using T1-weighted imaging templates included in the SPM package. The FMZ BPs were spatially normalized with the same parameters used to spatially normalize the MRI. The spatially normalized FMZ BPs were smoothed with an isotropic Gaussian kernel of 8 mm. Global counts were estimated using proportional scaling. The threshold value was set at 0.80.

We performed a separate linear regression for each voxel, in which the normalized BP image voxel in each scan was the dependent variable and each WEI score was the independent variable, as described previously [25].

Table 1
Clinical features among the 10 ALS patients.

Total number of patients	10
Male/female ratio	6:4
Age (years, mean \pm SD)	61.1 \pm 11.7
Months from onset (mean \pm SD)	19.1 \pm 5.1
ALS-FRS-R (total) (mean \pm SD)	35.6 \pm 8.4
ALS-FRS-R (1–3) (mean \pm SD)	7.0 \pm 4.6

ALS-FRS-R: ALS functional rating scale revised, SD: standard deviation.

Download English Version:

<https://daneshyari.com/en/article/8281355>

Download Persian Version:

<https://daneshyari.com/article/8281355>

[Daneshyari.com](https://daneshyari.com)